The rationale behind using combination of PARP inhibitors in DDR-defective cancer cells is that these prevent single-strand DNA repair, which increases DNA damage, enhancing the load of tumor mutations, thus making the tumors more immunologically “hot” [108]. Here, PARP1 is linked to cancer.